MedTrace Logo

Japanese Dose-Response Study of Rimonabant in Obese Patients

NCT00459004 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 527

Last updated 2009-04-07

No results posted yet for this study

Summary

The primary objective is to verify the dose-response relationship of rimonabant on body weight change.

The secondary objectives are to compare the effect of 3 doses of SR141716 to placebo, on body weight loss and on secondary criteria associated with comorbidities, and to evaluate the safety and the pharmacokinetics of SR141716.

Conditions

Interventions

DRUG

rimonabant (SR141716)

Sponsors & Collaborators

Principal Investigators

  • Kohji SHIRAI, Professor · Toho University Sakura Medical Center, Japan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2006-04-30
Completion
2006-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00459004 on ClinicalTrials.gov